Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + DFN-15
|
DCE5BOA
|
ABIRATERONE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
ABIRATERONE + DFN-15
|
DC3FKF9
|
ABIRATERONE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
ABIRATERONE + DFN-15
|
DCKRLRB
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
ABIRATERONE + DFN-15
|
DCBTQ1M
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
ABIRATERONE + DFN-15
|
DCDJILT
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
ABIRATERONE + DFN-15
|
DC8D2B2
|
ABIRATERONE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
ABIRATERONE + DFN-15
|
DCD9UX8
|
ABIRATERONE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Amonafide + DFN-15
|
DCGRDY0
|
Amonafide
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Amonafide + DFN-15
|
DCY01FH
|
Amonafide
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Amonafide + DFN-15
|
DCJ0YEY
|
Amonafide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Amonafide + DFN-15
|
DC4UVDX
|
Amonafide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Amonafide + DFN-15
|
DCDBEHC
|
Amonafide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Amonafide + DFN-15
|
DCBQ1AC
|
Amonafide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Anastrozole + DFN-15
|
DCDF2FP
|
Anastrozole
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Anastrozole + DFN-15
|
DCNUK7U
|
Anastrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Anastrozole + DFN-15
|
DC5SZQ9
|
Anastrozole
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Anastrozole + DFN-15
|
DCPTXDJ
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Anastrozole + DFN-15
|
DCNOG3M
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Anastrozole + DFN-15
|
DCMY5RP
|
Anastrozole
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Anastrozole + DFN-15
|
DC610VJ
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[2] |
|
Anastrozole + DFN-15
|
DCP67XG
|
Anastrozole
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Arfolitixorin + DFN-15
|
DCP04RL
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
BIO-300 + DFN-15
|
DC73DIS
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
BIO-300 + DFN-15
|
DC2TBK7
|
BIO-300
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
BIO-300 + DFN-15
|
DCJHVZN
|
BIO-300
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Cabazitaxel + DFN-15
|
DCO795J
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCTHQRR
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCERJ69
|
Cabazitaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCHTZYT
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCDC5CJ
|
Cabazitaxel
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCLZ1K8
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[2] |
|
Cabazitaxel + DFN-15
|
DC48JTS
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Cabazitaxel + DFN-15
|
DC8H964
|
Cabazitaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Cabazitaxel + DFN-15
|
DC9IW87
|
Cabazitaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCSRCL3
|
Cabazitaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCFZ89L
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Cabazitaxel + DFN-15
|
DCB6CNG
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Crizotinib + DFN-15
|
DC2FXZN
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Crizotinib + DFN-15
|
DCZX3D3
|
Crizotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Crizotinib + DFN-15
|
DCO79DM
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Crizotinib + DFN-15
|
DCF6AZ3
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Crizotinib + DFN-15
|
DCSIWCZ
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Crizotinib + DFN-15
|
DCZ2KMJ
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Crizotinib + DFN-15
|
DC52GI0
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Crizotinib + DFN-15
|
DCKSBSY
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Crizotinib + DFN-15
|
DC3IJWX
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Crizotinib + DFN-15
|
DCM0W6A
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Dacarbazine + DFN-15
|
DCGUWKH
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Dacarbazine + DFN-15
|
DCET1CE
|
Dacarbazine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Dacarbazine + DFN-15
|
DCB90KT
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Dacarbazine + DFN-15
|
DCJWLM2
|
Dacarbazine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Dacarbazine + DFN-15
|
DC99E1C
|
Dacarbazine
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Dactinomycin + DFN-15
|
DCQ3LWD
|
Dactinomycin
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Dactinomycin + DFN-15
|
DCDZ3V3
|
Dactinomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Dactinomycin + DFN-15
|
DCIZ78Y
|
Dactinomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Dactinomycin + DFN-15
|
DC22D7I
|
Dactinomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Dactinomycin + DFN-15
|
DC8K8PZ
|
Dactinomycin
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Dactinomycin + DFN-15
|
DCZK8VZ
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Dactinomycin + DFN-15
|
DCQHD50
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Dactinomycin + DFN-15
|
DCEO2T3
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Dactinomycin + DFN-15
|
DCGF33H
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Dactinomycin + DFN-15
|
DCZ3RBW
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Dactinomycin + DFN-15
|
DCJ6BF1
|
Dactinomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Dactinomycin + DFN-15
|
DCMUUMC
|
Dactinomycin
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Dactinomycin + DFN-15
|
DCLMIZT
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Dactinomycin + DFN-15
|
DCTVYFT
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Dactinomycin + DFN-15
|
DC6LIVX
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Dactinomycin + DFN-15
|
DC2L83M
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Dactinomycin + DFN-15
|
DCKDZ5Y
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Dactinomycin + DFN-15
|
DCF2Z3N
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Dactinomycin + DFN-15
|
DCCNJGU
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Dactinomycin + DFN-15
|
DCJ5YL4
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Dactinomycin + DFN-15
|
DC5T4TN
|
Dactinomycin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Dexrazoxane + DFN-15
|
DCEN28C
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Pentostatin
|
DCGWBF5
|
Pentostatin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
DFN-15 + Pentostatin
|
DC6W472
|
Pentostatin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Pentostatin
|
DCKI8XB
|
Pentostatin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Fulvestrant
|
DC1I3Y7
|
Fulvestrant
|
Glioma (Cell Line: SF-539)
|
[2] |
|
DFN-15 + Lapatinib
|
DC4QU8V
|
Lapatinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
DFN-15 + Lapatinib
|
DC5CNFZ
|
Lapatinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
DFN-15 + Cyclophosphamide
|
DCBUUV2
|
Cyclophosphamide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
DFN-15 + Cyclophosphamide
|
DCADQ51
|
Cyclophosphamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
DFN-15 + Panobinostat
|
DCX9DNQ
|
Panobinostat
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
DFN-15 + Triapine
|
DCVYL6J
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
DFN-15 + 10-hydroxycamptothecin
|
DC7QM5P
|
10-hydroxycamptothecin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
DFN-15 + Pralatrexate
|
DC21VBZ
|
Pralatrexate
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Terameprocol
|
DC17SWV
|
Terameprocol
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
DFN-15 + Terameprocol
|
DCUYSN2
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
DFN-15 + Terameprocol
|
DCORIMS
|
Terameprocol
|
Glioma (Cell Line: SF-539)
|
[2] |
|
DFN-15 + Ifosfamide
|
DCY4GA0
|
Ifosfamide
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
DFN-15 + Ifosfamide
|
DCPJ7HL
|
Ifosfamide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
DFN-15 + Docetaxel
|
DCHG5GF
|
Docetaxel
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
DFN-15 + Docetaxel
|
DC0B46S
|
Docetaxel
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
DFN-15 + Docetaxel
|
DCKU2OM
|
Docetaxel
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
DFN-15 + Docetaxel
|
DCI2C1X
|
Docetaxel
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Docetaxel
|
DCEK7JE
|
Docetaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
DFN-15 + Docetaxel
|
DC3PVRA
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
DFN-15 + Docetaxel
|
DC3MEE4
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
DFN-15 + Docetaxel
|
DCNQWMS
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Docetaxel
|
DC4OR4C
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
DFN-15 + Docetaxel
|
DCOZMEC
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
DFN-15 + Docetaxel
|
DCDEIWJ
|
Docetaxel
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
DFN-15 + Docetaxel
|
DC5WTD9
|
Docetaxel
|
Glioma (Cell Line: SF-295)
|
[2] |
|
DFN-15 + Docetaxel
|
DCAWGAO
|
Docetaxel
|
Glioma (Cell Line: SF-539)
|
[2] |
|
DFN-15 + Docetaxel
|
DCJT5N2
|
Docetaxel
|
Glioma (Cell Line: SF-268)
|
[2] |
|
DFN-15 + Docetaxel
|
DCI5O5A
|
Docetaxel
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
DFN-15 + Docetaxel
|
DC9WORA
|
Docetaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
DFN-15 + Raloxifene
|
DCI1PGO
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + Raloxifene
|
DCV0O2D
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Raloxifene
|
DCCLEVY
|
Raloxifene
|
Glioma (Cell Line: SF-539)
|
[2] |
|
DFN-15 + Sirolimus
|
DCKCCAG
|
Sirolimus
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + Sirolimus
|
DCNBVS0
|
Sirolimus
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
DFN-15 + Sirolimus
|
DCGHVA0
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
DFN-15 + Sirolimus
|
DC0UQNO
|
Sirolimus
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
DFN-15 + Sirolimus
|
DC63B4X
|
Sirolimus
|
Glioma (Cell Line: SF-295)
|
[2] |
|
DFN-15 + Sirolimus
|
DC1W97U
|
Sirolimus
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
DFN-15 + Sirolimus
|
DC5MX1Z
|
Sirolimus
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
DFN-15 + TEM
|
DCFDEJ7
|
TEM
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Idarubicin
|
DCDZI1K
|
Idarubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + Idarubicin
|
DCTRN7K
|
Idarubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Idarubicin
|
DCVJANQ
|
Idarubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
DFN-15 + Idarubicin
|
DC7QM1P
|
Idarubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
DFN-15 + Chlorambucil
|
DCGILBE
|
Chlorambucil
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Chlorambucil
|
DCSAC1I
|
Chlorambucil
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
DFN-15 + Chlorambucil
|
DCOE0JA
|
Chlorambucil
|
Glioma (Cell Line: SF-295)
|
[2] |
|
DFN-15 + Sorafenib
|
DCSYGJZ
|
Sorafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + Sorafenib
|
DC9DHCW
|
Sorafenib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
DFN-15 + Azacitidine
|
DC4N4OR
|
Azacitidine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + Pomalidomide
|
DCNVOIS
|
Pomalidomide
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
DFN-15 + Vinflunine
|
DCUUQPO
|
Vinflunine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + Vinflunine
|
DCG5YAD
|
Vinflunine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
DFN-15 + Vinflunine
|
DC98440
|
Vinflunine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
DFN-15 + Vinflunine
|
DC1ZLKQ
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Vinflunine
|
DC7NT7W
|
Vinflunine
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
DFN-15 + Vinflunine
|
DCZ7IPY
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
DFN-15 + Mepacrine
|
DC6NPUR
|
Mepacrine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
DFN-15 + Mepacrine
|
DCMYGI1
|
Mepacrine
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
DFN-15 + Mepacrine
|
DCGBUB9
|
Mepacrine
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
DFN-15 + Mepacrine
|
DC6PX5G
|
Mepacrine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
DFN-15 + Taxol
|
DCPI08Q
|
Taxol
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
DFN-15 + Taxol
|
DCSNZAC
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Taxol
|
DCGNPDY
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
DFN-15 + Taxol
|
DCSXDDC
|
Taxol
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
DFN-15 + Taxol
|
DCB0A4D
|
Taxol
|
Glioma (Cell Line: SF-268)
|
[2] |
|
DFN-15 + Taxol
|
DC9MBVJ
|
Taxol
|
Glioma (Cell Line: SF-295)
|
[2] |
|
DFN-15 + Taxol
|
DC3T71J
|
Taxol
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
DFN-15 + PMID28870136-Compound-43
|
DCU09YS
|
PMID28870136-Compound-43
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
DFN-15 + FORMESTANE
|
DCRBZSK
|
FORMESTANE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + FORMESTANE
|
DCD11NF
|
FORMESTANE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
DFN-15 + FORMESTANE
|
DCRZMB8
|
FORMESTANE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
DFN-15 + Busulfan
|
DCVCLTG
|
Busulfan
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Busulfan
|
DCEVM0C
|
Busulfan
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Busulfan
|
DCQQP4U
|
Busulfan
|
Glioma (Cell Line: SF-539)
|
[2] |
|
DFN-15 + Dasatinib
|
DCIDC3Y
|
Dasatinib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Dasatinib
|
DCV0W93
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
DFN-15 + Dasatinib
|
DCOBAIV
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
DFN-15 + Dasatinib
|
DCI10GN
|
Dasatinib
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
DFN-15 + Dasatinib
|
DCWEVTB
|
Dasatinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
DFN-15 + Dasatinib
|
DCXDJHG
|
Dasatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
DFN-15 + Dasatinib
|
DC0TJJ3
|
Dasatinib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
DFN-15 + Hepzato
|
DCOM1GF
|
Hepzato
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
DFN-15 + Plicamycin
|
DCKLX2T
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
DFN-15 + Triapine
|
DCCGHSA
|
Triapine
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
DFN-15 + 10-hydroxycamptothecin
|
DCRWZ5B
|
10-hydroxycamptothecin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
DFN-15 + SCH 727965
|
DCORFBU
|
SCH 727965
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
DFN-15 + SCH 727965
|
DCPTSQD
|
SCH 727965
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
DFN-15 + SCH 727965
|
DCCGK0M
|
SCH 727965
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
DFN-15 + Ifosfamide
|
DCMK81K
|
Ifosfamide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
DFN-15 + Docetaxel
|
DCBIHXB
|
Docetaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
DFN-15 + Docetaxel
|
DC2DQZS
|
Docetaxel
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
DFN-15 + Docetaxel
|
DCKMOCR
|
Docetaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
DFN-15 + Docetaxel
|
DCWDHTD
|
Docetaxel
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + Docetaxel
|
DC1K44G
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
DFN-15 + Docetaxel
|
DCX4Y41
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
DFN-15 + Docetaxel
|
DC97INV
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
DFN-15 + Raloxifene
|
DCUOWWW
|
Raloxifene
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
DFN-15 + Sirolimus
|
DCOZE9L
|
Sirolimus
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
DFN-15 + Sirolimus
|
DCA5U4K
|
Sirolimus
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
DFN-15 + Sirolimus
|
DCNAHF7
|
Sirolimus
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + Sirolimus
|
DCI0SEP
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
DFN-15 + Sirolimus
|
DCF8BBO
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
DFN-15 + Mitomycin
|
DCYDGNT
|
Mitomycin
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + SY-1425
|
DCGOOAU
|
SY-1425
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + SY-1425
|
DCYZOEB
|
SY-1425
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
DFN-15 + Idarubicin
|
DC0PKSU
|
Idarubicin
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
DFN-15 + Idarubicin
|
DCUXW38
|
Idarubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
DFN-15 + Azacitidine
|
DCQ1NKA
|
Azacitidine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + Azacitidine
|
DCBN8A7
|
Azacitidine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
DFN-15 + Vinflunine
|
DCYHMLY
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
DFN-15 + Mepacrine
|
DCNHXUS
|
Mepacrine
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
DFN-15 + Mepacrine
|
DCIJRLK
|
Mepacrine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + Taxol
|
DCRKTDX
|
Taxol
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
DFN-15 + Taxol
|
DCOOPCN
|
Taxol
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + Taxol
|
DCI1ARZ
|
Taxol
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
DFN-15 + PMID28870136-Compound-43
|
DCEROKL
|
PMID28870136-Compound-43
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
DFN-15 + Aminolevulinic Acid Hydrochloride
|
DCV6Q9M
|
Aminolevulinic Acid Hydrochloride
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
DFN-15 + Dasatinib
|
DC2KM85
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
DFN-15 + Dasatinib
|
DCZ11C5
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
DFN-15 + Pentostatin
|
DCP3U3Q
|
Pentostatin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Fulvestrant
|
DC1KIK5
|
Fulvestrant
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
DFN-15 + Fulvestrant
|
DCNOTA7
|
Fulvestrant
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
DFN-15 + Hepzato
|
DC6352A
|
Hepzato
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Hepzato
|
DC52MGE
|
Hepzato
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Hepzato
|
DCAAE55
|
Hepzato
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Ixabepilone
|
DCUPWWL
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Lapatinib
|
DCZHX99
|
Lapatinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
DFN-15 + Cyclophosphamide
|
DC8T5P6
|
Cyclophosphamide
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
DFN-15 + Cyclophosphamide
|
DC948YS
|
Cyclophosphamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
DFN-15 + Plicamycin
|
DC4J5I6
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
DFN-15 + Plicamycin
|
DC8BEKP
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Plicamycin
|
DCN4GKD
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
DFN-15 + Plicamycin
|
DC5TCIL
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
DFN-15 + Plicamycin
|
DCOP8LE
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
DFN-15 + Nilotinib
|
DCNBZC8
|
Nilotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Nilotinib
|
DCA7PGM
|
Nilotinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
DFN-15 + Nilotinib
|
DCPRH88
|
Nilotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
DFN-15 + Nilotinib
|
DCWAPQB
|
Nilotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
DFN-15 + Nilotinib
|
DCM798H
|
Nilotinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
DFN-15 + Triapine
|
DC3DNKP
|
Triapine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
DFN-15 + Pralatrexate
|
DC00OJ5
|
Pralatrexate
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + Pralatrexate
|
DC0NSEC
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Pralatrexate
|
DCC531X
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
DFN-15 + Pralatrexate
|
DC89OKB
|
Pralatrexate
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
DFN-15 + Terameprocol
|
DCU5KYI
|
Terameprocol
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
DFN-15 + Terameprocol
|
DC1L534
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
DFN-15 + Terameprocol
|
DC4NDKD
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Terameprocol
|
DC69APN
|
Terameprocol
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
DFN-15 + SCH 727965
|
DCKXTS7
|
SCH 727965
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + SCH 727965
|
DCCVLXE
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
DFN-15 + SCH 727965
|
DCV0TJK
|
SCH 727965
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
DFN-15 + Ifosfamide
|
DCEFAU9
|
Ifosfamide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Ifosfamide
|
DCPKT00
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Ifosfamide
|
DCGK0PH
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Ifosfamide
|
DCSLUH0
|
Ifosfamide
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
DFN-15 + Ifosfamide
|
DCYGLT9
|
Ifosfamide
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
DFN-15 + Docetaxel
|
DC9E9TK
|
Docetaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + Docetaxel
|
DC9F9ZG
|
Docetaxel
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Docetaxel
|
DCHYZ4B
|
Docetaxel
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
DFN-15 + Docetaxel
|
DCSDAH1
|
Docetaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
DFN-15 + Docetaxel
|
DCMPLMG
|
Docetaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Docetaxel
|
DC1UU39
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
DFN-15 + Docetaxel
|
DCIAJTB
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Docetaxel
|
DCSREZV
|
Docetaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
DFN-15 + Docetaxel
|
DCO902R
|
Docetaxel
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
DFN-15 + Docetaxel
|
DC6JMK0
|
Docetaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
DFN-15 + Docetaxel
|
DCSGYIJ
|
Docetaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
DFN-15 + Docetaxel
|
DCIDDO0
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
DFN-15 + Docetaxel
|
DC4RNAP
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
DFN-15 + Docetaxel
|
DCJ93D8
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
DFN-15 + Docetaxel
|
DC399XB
|
Docetaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
DFN-15 + Docetaxel
|
DCYL7DC
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Docetaxel
|
DC7E54J
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
DFN-15 + Docetaxel
|
DC6JFHL
|
Docetaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
DFN-15 + Docetaxel
|
DC66KPL
|
Docetaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
DFN-15 + Docetaxel
|
DCN2W9Q
|
Docetaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
DFN-15 + Raloxifene
|
DCXQKWI
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
DFN-15 + Raloxifene
|
DCI7CIM
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
DFN-15 + Raloxifene
|
DCAHGUO
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Raloxifene
|
DCYP8M5
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
DFN-15 + Bendamustine hydrochloride
|
DCOFVR0
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Bendamustine hydrochloride
|
DCQT2PG
|
Bendamustine hydrochloride
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
DFN-15 + Sirolimus
|
DC1H5CM
|
Sirolimus
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Sirolimus
|
DC8I10T
|
Sirolimus
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
DFN-15 + Sirolimus
|
DCAL6WM
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Sirolimus
|
DC9IFZH
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Sirolimus
|
DCFUNWZ
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
DFN-15 + Sirolimus
|
DC7Q7JB
|
Sirolimus
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
DFN-15 + Sirolimus
|
DCS61SG
|
Sirolimus
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
DFN-15 + Mitomycin
|
DCJ67LR
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
DFN-15 + SY-1425
|
DCKFZ16
|
SY-1425
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
DFN-15 + SY-1425
|
DC53O5U
|
SY-1425
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
DFN-15 + SY-1425
|
DCEPIN8
|
SY-1425
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
DFN-15 + SY-1425
|
DCBL4FV
|
SY-1425
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
DFN-15 + Vincristine
|
DCY7STK
|
Vincristine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
DFN-15 + Vincristine
|
DCFQORL
|
Vincristine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
DFN-15 + Altretamine
|
DCUOUGJ
|
Altretamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
DFN-15 + Altretamine
|
DC0FP06
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
DFN-15 + Idarubicin
|
DCID8XB
|
Idarubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Idarubicin
|
DC9WVLQ
|
Idarubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Idarubicin
|
DCE0OYX
|
Idarubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
DFN-15 + Idarubicin
|
DC4CM9K
|
Idarubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
DFN-15 + Idarubicin
|
DCKMVPF
|
Idarubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Idarubicin
|
DCSZCNT
|
Idarubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
DFN-15 + Idarubicin
|
DCYX5N0
|
Idarubicin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
DFN-15 + Imatinib
|
DC6S52T
|
Imatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
DFN-15 + Imatinib
|
DCASB7B
|
Imatinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
DFN-15 + Sorafenib
|
DCOADX6
|
Sorafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + Sorafenib
|
DC5U7B1
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + ER819762
|
DCY25BG
|
ER819762
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
DFN-15 + ER819762
|
DCRU2NJ
|
ER819762
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
DFN-15 + Azacitidine
|
DCV0X9T
|
Azacitidine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Azacitidine
|
DCVTEHB
|
Azacitidine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Azacitidine
|
DCINM0I
|
Azacitidine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
DFN-15 + Azacitidine
|
DCDFCE4
|
Azacitidine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
DFN-15 + Pomalidomide
|
DC9PUFZ
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
DFN-15 + Pomalidomide
|
DCL3VCY
|
Pomalidomide
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
DFN-15 + Vinflunine
|
DCMQNBG
|
Vinflunine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Vinflunine
|
DCGSSDF
|
Vinflunine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
DFN-15 + Vinflunine
|
DC7T3FR
|
Vinflunine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
DFN-15 + Vinflunine
|
DCE0YDY
|
Vinflunine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
DFN-15 + Mepacrine
|
DC9RMJR
|
Mepacrine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + Mepacrine
|
DC5M7I7
|
Mepacrine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Mepacrine
|
DC2UYYO
|
Mepacrine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Mepacrine
|
DCZ8H2X
|
Mepacrine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
DFN-15 + Mepacrine
|
DCE8EK1
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
DFN-15 + Mepacrine
|
DC4C9X9
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
DFN-15 + Mepacrine
|
DC25HUA
|
Mepacrine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
DFN-15 + Mepacrine
|
DCI2KKX
|
Mepacrine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
DFN-15 + Mepacrine
|
DC9EKV1
|
Mepacrine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
DFN-15 + Taxol
|
DC0J66X
|
Taxol
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Taxol
|
DCL1G2S
|
Taxol
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
DFN-15 + Taxol
|
DCFSRKM
|
Taxol
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Taxol
|
DCJCY6M
|
Taxol
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
DFN-15 + Taxol
|
DC7IV5F
|
Taxol
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
DFN-15 + Taxol
|
DCOMFQQ
|
Taxol
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
DFN-15 + Fludarabine
|
DCYOM9Y
|
Fludarabine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
DFN-15 + PMID28870136-Compound-43
|
DCXZ7GH
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + PMID28870136-Compound-43
|
DC71JW8
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + FORMESTANE
|
DCTME0M
|
FORMESTANE
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + FORMESTANE
|
DCQ78RY
|
FORMESTANE
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
DFN-15 + Aminolevulinic Acid Hydrochloride
|
DCR6PBH
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Aminolevulinic Acid Hydrochloride
|
DCR974N
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
DFN-15 + Aminolevulinic Acid Hydrochloride
|
DCGIN10
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
DFN-15 + Aminolevulinic Acid Hydrochloride
|
DC6KSYC
|
Aminolevulinic Acid Hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
DFN-15 + Aminolevulinic Acid Hydrochloride
|
DCTVX8C
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
DFN-15 + Aminolevulinic Acid Hydrochloride
|
DCJY69O
|
Aminolevulinic Acid Hydrochloride
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
DFN-15 + Estramustine
|
DC8TWPZ
|
Estramustine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
DFN-15 + Estramustine
|
DCRGAUF
|
Estramustine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
DFN-15 + Digitoxin
|
DCRH3X1
|
Digitoxin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
DFN-15 + Busulfan
|
DCWLOWE
|
Busulfan
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + Busulfan
|
DCY5V6U
|
Busulfan
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Dasatinib
|
DC1S66Q
|
Dasatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
DFN-15 + Dasatinib
|
DC2XVAB
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Dasatinib
|
DCOK1NW
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
DFN-15 + Dasatinib
|
DCWK2K9
|
Dasatinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Epirubicin + DFN-15
|
DC8FKKH
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Epirubicin + DFN-15
|
DCT94J0
|
Epirubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Epirubicin + DFN-15
|
DCFY8CM
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Epirubicin + DFN-15
|
DCR5W5M
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Epirubicin + DFN-15
|
DC2VOX3
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Epirubicin + DFN-15
|
DC130R4
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Epirubicin + DFN-15
|
DC6E1RE
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Epirubicin + DFN-15
|
DCHUA1O
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Epirubicin + DFN-15
|
DCWSUIY
|
Epirubicin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
Epirubicin + DFN-15
|
DC4JW8M
|
Epirubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Epirubicin + DFN-15
|
DCMCWRL
|
Epirubicin
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Epirubicin + DFN-15
|
DCUMOMN
|
Epirubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Epirubicin + DFN-15
|
DCW9DPF
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Epirubicin + DFN-15
|
DCID271
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Epirubicin + DFN-15
|
DCTNT0E
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Epirubicin + DFN-15
|
DC21SFI
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Epirubicin + DFN-15
|
DCNM0WO
|
Epirubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Epirubicin + DFN-15
|
DCPW6SL
|
Epirubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Epirubicin + DFN-15
|
DC0A5D5
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Epirubicin + DFN-15
|
DC6V772
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Epirubicin + DFN-15
|
DC3UVSE
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Epirubicin + DFN-15
|
DCOOZ90
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Epirubicin + DFN-15
|
DCJYP37
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Epirubicin + DFN-15
|
DCYPERS
|
Epirubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Epirubicin + DFN-15
|
DC7U70M
|
Epirubicin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Epirubicin + DFN-15
|
DCO5JLC
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Epirubicin + DFN-15
|
DCINDT9
|
Epirubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Epirubicin + DFN-15
|
DCEGT94
|
Epirubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Epirubicin + DFN-15
|
DCCIA4X
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Epirubicin + DFN-15
|
DCRBIWD
|
Epirubicin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Gefitinib + DFN-15
|
DCW48H1
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Gefitinib + DFN-15
|
DCM8F6B
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Indazole derivative 5 + DFN-15
|
DCH3W3Y
|
Indazole derivative 5
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Indazole derivative 5 + DFN-15
|
DCGG6OO
|
Indazole derivative 5
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Indazole derivative 5 + DFN-15
|
DCMO2OW
|
Indazole derivative 5
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Indazole derivative 5 + DFN-15
|
DCYTCR5
|
Indazole derivative 5
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCQI8M3
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DCUAPXD
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DC8PO7S
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DCETGFL
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DCGPRM3
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DCX0IL5
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DCT0GME
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DC32L2P
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DCWW6BL
|
Indazole derivative 5
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Indazole derivative 5 + DFN-15
|
DC0V8ZE
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
JNK-IN-8 + DFN-15
|
DCYUKX3
|
JNK-IN-8
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
JNK-IN-8 + DFN-15
|
DC51BU2
|
JNK-IN-8
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Letrozole + DFN-15
|
DC4TGP1
|
Letrozole
|
Adenocarcinoma (Cell Line: NCIH23)
|
[2] |
|
Letrozole + DFN-15
|
DCCZOF0
|
Letrozole
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Letrozole + DFN-15
|
DCMEGAB
|
Letrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Letrozole + DFN-15
|
DCL46FT
|
Letrozole
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
Letrozole + DFN-15
|
DCZ3QWV
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Letrozole + DFN-15
|
DC9N9Y5
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Mechlorethamine + DFN-15
|
DCQRZMV
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Mechlorethamine + DFN-15
|
DCCP1DU
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Mechlorethamine + DFN-15
|
DCIGY58
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Mechlorethamine + DFN-15
|
DC705YT
|
Mechlorethamine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Mechlorethamine + DFN-15
|
DC0ACJE
|
Mechlorethamine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Mechlorethamine + DFN-15
|
DCH92KF
|
Mechlorethamine
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Picoplatin + DFN-15
|
DCD3GLE
|
Picoplatin
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Picoplatin + DFN-15
|
DCTGZ41
|
Picoplatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + DFN-15
|
DCV9PSZ
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + DFN-15
|
DC6CLI2
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + DFN-15
|
DCHP3UL
|
Raloxifene
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + DFN-15
|
DCGS5ZM
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + DFN-15
|
DCHVUNU
|
Raloxifene
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + DFN-15
|
DCZY0QN
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + DFN-15
|
DC1D8VE
|
Raloxifene
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + DFN-15
|
DCUFWXG
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Ruxolitinib + DFN-15
|
DCVX78B
|
Ruxolitinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Ruxolitinib + DFN-15
|
DC1CT0U
|
Ruxolitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Ruxolitinib + DFN-15
|
DC5BQOZ
|
Ruxolitinib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Ruxolitinib + DFN-15
|
DCT455K
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Ruxolitinib + DFN-15
|
DCTR14O
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Ruxolitinib + DFN-15
|
DCCMHKS
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Thioguanine + DFN-15
|
DC1N0M2
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Thioguanine + DFN-15
|
DC109BC
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Thioguanine + DFN-15
|
DCCKAJI
|
Thioguanine
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Topotecan + DFN-15
|
DCMODTR
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Topotecan + DFN-15
|
DCI3FBW
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Topotecan + DFN-15
|
DC1U9BW
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Topotecan + DFN-15
|
DCQB8NQ
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Topotecan + DFN-15
|
DCR9AM2
|
Topotecan
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Topotecan + DFN-15
|
DCMHL31
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Topotecan + DFN-15
|
DCY4GRK
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Topotecan + DFN-15
|
DC14MIJ
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Topotecan + DFN-15
|
DCRTPF4
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Topotecan + DFN-15
|
DCNCZFO
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Topotecan + DFN-15
|
DC51OL4
|
Topotecan
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Trifluridine + DFN-15
|
DC0NF83
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Trifluridine + DFN-15
|
DCJ4OZA
|
Trifluridine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Trifluridine + DFN-15
|
DCG6GEQ
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Uracil mustard + DFN-15
|
DCCCMD1
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Vandetanib + DFN-15
|
DCWRJ3V
|
Vandetanib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Vandetanib + DFN-15
|
DCEFF28
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Vandetanib + DFN-15
|
DCYXQPQ
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Vandetanib + DFN-15
|
DCULRGO
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vandetanib + DFN-15
|
DCM9ORN
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vandetanib + DFN-15
|
DCCW9DE
|
Vandetanib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vandetanib + DFN-15
|
DCHKH6P
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vemurafenib + DFN-15
|
DC41RW6
|
Vemurafenib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Vemurafenib + DFN-15
|
DC199T7
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Vemurafenib + DFN-15
|
DCFDC2E
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Vemurafenib + DFN-15
|
DCZURZ9
|
Vemurafenib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Vemurafenib + DFN-15
|
DC5NRVU
|
Vemurafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vemurafenib + DFN-15
|
DCZV3S1
|
Vemurafenib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Vemurafenib + DFN-15
|
DCXD3OD
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Vemurafenib + DFN-15
|
DCWVU15
|
Vemurafenib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Vemurafenib + DFN-15
|
DCUOS6X
|
Vemurafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Vemurafenib + DFN-15
|
DCB6164
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vemurafenib + DFN-15
|
DCPNU21
|
Vemurafenib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Vismodegib + DFN-15
|
DCIQCIK
|
Vismodegib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Vismodegib + DFN-15
|
DCUC863
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Vismodegib + DFN-15
|
DCKPCB7
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Vismodegib + DFN-15
|
DC3S44I
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Vismodegib + DFN-15
|
DCTDW6T
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vismodegib + DFN-15
|
DCEFQ6Y
|
Vismodegib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vismodegib + DFN-15
|
DC75BRB
|
Vismodegib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Vismodegib + DFN-15
|
DC76A14
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vismodegib + DFN-15
|
DCDTEGF
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vismodegib + DFN-15
|
DCBOC2N
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Vismodegib + DFN-15
|
DCSXG3M
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Vismodegib + DFN-15
|
DCBMZ11
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Vismodegib + DFN-15
|
DCI6SDA
|
Vismodegib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Vismodegib + DFN-15
|
DCHIKQJ
|
Vismodegib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Vismodegib + DFN-15
|
DC5GI4U
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vismodegib + DFN-15
|
DCQT51H
|
Vismodegib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
